Performance of Recommended Screening Tests for Undiagnosed Diabetes and Dysglycemia
- Deborah B. Rolka, MS1,
- K. M. Venkat Narayan, MD1,
- Theodore J. Thompson, MS1,
- Dona Goldman, BSN, MPH2,
- Joann Lindenmayer, DVM, MPH2,
- Kate Alich, MS, RD3,
- Darcy Bacall, RN, CDE3,
- Evan M. Benjamin, MD4,
- Betty Lamb, RN, MSN1,
- Dennis O. Stuart, MD5 and
- Michael M. Engelgau, MD1
- 1Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, Georgia
- 2Rhode Island Department of Health, Providence, Rhode Island
- 3Massachusetts Department of Public Health, Boston, Massachusetts
- 4Baystate Medical Center, Springfield, Massachusetts
- 5Robeson Health Care Corporation, Fairmont, North Carolina
Abstract
OBJECTIVE—To evaluate the performance, in settings typical of opportunistic and community screening programs, of screening tests currently recommended by the American Diabetes Association (ADA) for detecting undiagnosed diabetes.
RESEARCH DESIGN AND METHODS—Volunteers aged ≥20 years without previously diagnosed diabetes (n = 1,471) completed a brief questionnaire and underwent recording of postprandial time and measurement of capillary blood glucose (CBG) with a portable sensor. Participants subsequently underwent a 75-g oral glucose tolerance test; fasting serum glucose (FSG) and 2-h postload serum glucose (2-h SG) concentrations were measured. The screening tests we studied included the ADA risk assessment questionnaire, the recommended CBG cut point of 140 mg/dl, and an alternative CBG cut point of 120 mg/dl. Each screening test was evaluated against several diagnostic criteria for diabetes (FSG ≥126 mg/dl, 2-h SG ≥200 mg/dl, or either) and dysglycemia (FSG ≥110 mg/dl, 2-h SG ≥140 mg/dl, or either).
RESULTS—Among all participants, 10.7% had undiagnosed diabetes (FSG ≥126 or 2-h SG ≥200 mg/dl), 52.1% had a positive result on the questionnaire, 9.5% had CBG ≥140 mg/dl, and 18.4% had CBG ≥120 mg/dl. The questionnaire was 72–78% sensitive and 50–51% specific for the three diabetes diagnostic criteria; CBG ≥140 mg/dl was 56–65% sensitive and 95–96% specific, and CBG ≥120 mg/dl was 75–84% sensitive and 86–90% specific. CBG ≥120 mg/dl was 44–62% sensitive and 89–90% specific for dysglycemia.
CONCLUSIONS—Low specificity may limit the usefulness of the ADA questionnaire. Lowering the cut point for a casual CBG test (e.g., to 120 mg/dl) may improve sensitivity and still provide adequate specificity.
- 2-h SG, 2-h postload serum glucose
- ADA, American Diabetes Association
- CBG, capillary blood glucose
- FSG, fasting serum glucose
- IFG, impaired fasting glucose
- IGT, impaired glucose tolerance
- OGTT, oral glucose tolerance test
- WHO, World Health Organization
Footnotes
-
Address correspondence and reprint requests to Deborah B. Rolka, Mailstop K-10, 4770 Buford Highway NE, Atlanta, GA 30341. E-mail: drolka{at}cdc.gov.
Received for publication 6 March 2001 and accepted in revised form 26 July 2001.
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.














